Q2i receives NIH / NIDA grant to develop and evaluate digital technologies to improve primary care drug delivery

<pre><pre>Q2i receives NIH / NIDA grant to develop and evaluate digital technologies to improve primary care drug delivery

BOSTON. January 7, 2020 / PRNewswire / – Q2i, a provider of digital health technology that helps improve the availability and success of opioid use disorder (MOUD) drugs, announced today that it is one of the National Institute on Drug Abuse The Institute of Health (NIH) received a grant. The scholarship is part of the long-term addiction helpSM Initiative or NIH HEAL initiativeSMlaunched in April 2018 Improve prevention and treatment strategies for opioid abuse and addiction, and improve pain management.

UCLA is the academic partner of Q2i for this project and leads the research on test optimization and evaluation of Q2i's digital health technology OARS. The aim is to increase the availability of MOUD, especially suboxone (buprenorphine / naloxone), initiation and compliance, and ultimately, abstinence from opioids in primary care.

MOUD involves the use of FDA-approved drugs such as methadone, buprenorphine or naloxone in combination with counseling and behavioral therapies to provide a "whole patient" approach to the treatment of OUD. MOUD is highly effective in reducing opioid use, but is limited by the number of providers who treat patients, especially in primary care.

Q2i's OARS technology includes a healthcare team portal and mobile patient application. It improves the success of MOUD programs by providing real-time insight, analysis and trend analysis, as well as improved connection and support between health teams and their patients.

DR. Steven Shoptawwho directs the research on UCLA said: "OARS interacts with the electronic health record to help primary care providers and their patients improve the results for MOUD. If it is effective, the OARS tool will improve patient access, the number of providers that provide MOUD, increase and ultimately increase usage of treatment against the current opioid epidemic. "

Steven Jenkins, CEO of Q2i, said: "OARS is an existing Q2i technology that has been in development and early use for over three years. Preliminary feedback from patients and providers indicates improved provider experience, a high level of patient loyalty and better Adherence to treatment plans. " We look forward to the opportunity to work with you UCLA to improve and develop the OARS in order to adapt it to the specific needs of general practitioners. "

Phase 1 of the research study will focus on health organizations New Hampshire, According to the NIH New Hampshire is among the five countries with the highest rate of opioid-related deaths, more than double the national average rate in 2017.

"These funds are a much-needed investment in moving existing medical research from the laboratory to treatment centers, and in developing new, innovative methods for treating opioid addiction and restoring patients." said NH Senator Shaheen.

"Tackling the devastating opioid epidemic in our country requires innovative approaches to treatment, prevention and recovery – and that is exactly why these federal grants are crucial." said NH Senator Hassan.


similar links